The critical role of signals transmitted via TNF ligands and receptors in mediating inflammation, cancer, and immunity has been well established in the literature. This understanding has been harnessed on the drug development frontier to mediate the pro-inflammatory properties of TNF signaling using ligand-neutralizing antibodies (eg. Remicade®) or soluble receptors (eg. Enbrel®). Similar strategies have sought to use recombinant TNF ligands to enhance, for instance, anti-viral and anti-cancer immune activation.
One limitation of this strategy is the inherent instability of recombinant ligands, and their inability to effectively mimic the natural clustering of TNF receptors on the cell surface required for immune activation. Oligomerization of TNF ligands using enhancers (eg. cross-linking antibodies), and expression of self-oligomerizing chimeric proteins (eg. Enzo MEGA® ligands) have been shown to improve stability and significantly enhance immune activation compared to that achieved with recombinant ligands alone (see figure below).
Enzo Life Sciences offers a diverse collection of enhanced ligands for use in immune activation studies. Our experience in the design and large-scale production of complex, high-purity, low endotoxin protein constructs results in enhanced ligands with the purity, stability, and consistency to deliver results you can trust for the duration of your study.
Enhance Immune Activation with MEGACD40L® Protein
B cell lymphocyte activation by various CD40L constructs. PBMCs were treated for 48 hrs in serum free media containing serially diluted MEGACD40L® Protein (ALX-522-110), CD40L + 2ug/mL Enhancer, or CD40L. Cells were dual-stained with anti-human CD19–PE and anti-human CD86–APC and analyzed by flow cytometry. Data are presented as the percent of CD19+ B cells that co-stain as CD86+.
MEGACD40L® Protein (soluble) (human), (recombinant) |
||||||
| High activity, high purity CD40L protein for co-stimulatory activation of an immune response | ||||||
| Produced in CHO cells. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag., ≥90% (SDS-PAGE) | Print as PDF | ||||||
| ALX-522-110-C010 | 10 µg | 670.00 USD |  |
|||
| Do you need bulk/larger quantities? | ||||||
MEGACD40L® Protein (soluble) (mouse), (recombinant) |
||||||
| High activity, high purity CD40L protein for co-stimulatory activation of an immune response | ||||||
| Produced in CHO cells. The extracellular domain of mouse CD40L (CD154) (aa 115-260) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag., ≥95% (SDS-PAGE) | Print as PDF | ||||||
| ALX-522-120-C010 | 10 µg | 716.00 USD | |
|||
| Do you need bulk/larger quantities? | ||||||
SUPERFASLIGAND® Protein (soluble) (human), (recombinant) |
||||||
| Fas ligand with improved stability providing significantly enhanced immune activation. | ||||||
| Produced in HEK 293 cells. The extracellular domain of human FasL (APO-1L; CD95L; CD178) (aa 103-281) is fused at the N-terminus to a linker peptide (26 aa) and a FLAG®-tag. Glycosylation of rhs SUPERFASLIGAND® is similar to natural human FasL., ≥95% (SDS-PAGE), ELISA | Print as PDF | ||||||
| ALX-522-020-C005 | 5 µg | 366.00 USD | |
|||
| ALX-522-020-3005 | 3x5 µg | SuperPack | 850.00 USD | |
||
| Do you need bulk/larger quantities? | ||||||
KillerTRAIL™ Protein (soluble) (human), (recombinant) |
||||||
| Enhanced ligand that utilizes the proprietary Killer™ linker peptide that promotes stability. | ||||||
| Produced in E. coli. The extracellular domain of human TRAIL (aa 95-281) is fused at the N-terminus to a His-tag and a linker peptide., ≥99% (SDS-PAGE, MS analysis) | Print as PDF | ||||||
| ALX-201-073-C020 | 20 µg | 572.00 USD | |
|||
| ALX-201-073-3020 | 3x20 µg | 1,181.00 USD | |
|||
| Do you need bulk/larger quantities? | ||||||
SUPERKILLERTRAIL® Protein (soluble) (human), (recombinant) |
||||||
| Enhanced ligand with improved stability providing significantly enhanced immune activation. | ||||||
| Produced in E. coli. The extracellular domain of human TRAIL (aa 95-281) is fused at the N-terminus to a His-tag and a linker peptide. The active multimeric conformation is stabilized by an inserted mutation allowing an additional CC-bridge., ≥98% (SDS-PAGE). MS analysis, <1% impurity (mainly Hsp70 protein from E. coli) | Print as PDF | ||||||
| ALX-201-115-C010 | 10 µg | 572.00 USD | |
|||
| ALX-201-115-3010 | 3x10 µg | 1,216.00 USD | |
|||
| Do you need bulk/larger quantities? | ||||||
ACRP30headless (mouse), (recombinant) |
||||||
| Produced in HEK 293 cells. The collagen domain of mouse ACRP30 (aa 18-111) is fused at the N-terminus to a linker peptide (8 aa) and a FLAG®-tag., ≥90% (SDS-PAGE) | Print as PDF | ||||||
| ALX-203-003-C010 | 10 µg | 362.00 USD | |
|||
| Do you need bulk/larger quantities? | ||||||
TNF-α (human), (recombinant) (cell culture grade) |
||||||
| 94948-59-1, Produced in yeast., ≥97% (SDS-PAGE) | Print as PDF | ||||||
| ALX-520-002-C010 | 10 µg | 235.00 USD | |
|||
| ALX-520-002-C050 | 50 µg | 848.00 USD | |
|||
| Do you need bulk/larger quantities? | ||||||
Fc (human):TNF-α (soluble) (human), (recombinant) |
||||||
| Produced in CHO cells. The extracellular domain of human TNF-α (aa 85-233) is fused at the N-terminus to the Fc portion of human IgG1 and a linker peptide (20 aa)., ≥90% (SDS-PAGE) | Print as PDF | ||||||
| ALX-522-087-C010 | 10 µg | Inquire for pricing | ||||
| Do you need bulk/larger quantities? | ||||||
TNF superfamily in inflammatory disease: translating basic insights. M. Croft, et al.; Trends Immunol. 33, 144 (2012).
Signaling pathways of the TNF superfamily: a double-edged sword. B. Aggarwal; Nat. Rev. Immunol. 3, 745 (2003).
A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response. I. Miconnet and G. Pantaleo; Vaccine. 26, 4006 (2008).
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003).
Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus ventors MVA and NYVAC expressing HIV antigens. C.E. Gomez, et al.; Vaccine 27, 3165 (2009).
